Prostate Cancer

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses how to determine which patient with prostate cancer is a candidate for docetaxel versus abiraterone acetate (Zytiga) and prednisone.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the future of MRI in prostate cancer.

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

William Oh, MD, reviews some of the biomarkers under investigation in GU cancers and possibilities for major advances in the field over the next few years.

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

A new test that can detect the existence of tumor activity is gaining credibility as a means of confirming the results of prostate biopsies, which have the potential to miss tumor cells.

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.